University of South Alabama

Gastroenterology Active Clinical Investigation Projects

Colon Cleansing for Diagnostic and Surgical Procedures

Lead Investigator: Jack A. DiPalma, M.D.
Investigational Agents: NuLytely, Cherry NuLytely, Half Lytely, SVPREP
Study Subjects: Patients undergoing colonoscopy.

Comparison of Preparations and Prokinetics for Capsule Endoscopy

Lead Investigator: Jack A. DiPalma, M.D.
Investigational Device: Small Bowel and Colon PillCam
Study Subject: Normal volunteers

Comparison of Lubiprostone and Placebo for the Relief of Constipation from Constipating Medications

Lead Investigator: Jack A. DiPalma, M.D.
Investigational Agent: Lubiprostone
Study Subject: Patients with constipation caused by medications 

Hepatology Research Projects:

Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Infected with Genotype 1- A Phase 3 Safety and Efficacy Study.
Lead Investigator: Jorge L. Herrera, M.D.
Investigational agents: Peginterferon alfa-2b, ribavirin and boceprevir
Study subjects: Genotype 1 hepatitis C patients who have never been treated in the past.

A Phase 3, Safety and Efficacy Study of Boceprevir in Subjects with Chronic Hepatitis C Genotype 1 who failed prior treatment with peginterferon/ribavirin
Lead Investigator: Jorge L. Herrera, M.D
. Investigational agents: Peginterferon alfa-2b, ribavirin and boceprevir
Study subjects: Genotype 1 hepatitis C patients who have been treated in the past with pegylated interferon and ribavirin and achieved a partial response to therapy but failed to clear virus.

Phase 3 Safety and Efficacy Study of Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin.
Lead Investigator: Jorge L. Herrera, M.D.
Investigational agents: Peginterferon alfa-2a, ribavirin and boceprevir
Study subjects: Genotype 1 hepatitis C patients who have been treated in the past with pegylated interferon and ribavirin and achieved a partial response to therapy but failed to clear virus.

A Single-Arm Study to Provide Boceprevir Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies
Lead Investigator: Jorge L. Herrera, M.D.
Investigational agents: Peginterferon alfa-2b, ribavirin and boceprevir
Study subjects: Patients who were enrolled in other studies that included boceprevir therapy in one arm, were randomized to the study group who did not receive boceprevir therapy and failed to clear virus.

Long-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH 503034 was Administered for the Treatment of Chronic Hepatitis C.
Lead Investigator: Jorge L. Herrera, M.D.
Investigational agents: None
Study subjects: Patients who were treated with boceprevir in any research study.

USA College of Medicine Clinical Trials

 

Text Only Options

Change the current font size: larger | default | smaller

Current color mode is Black on White, other available modes: Yellow on Black | Black on Cream

Current color mode is Yellow on Black, other available modes: Black on White | Black on Cream

Current color mode is Black on Cream, other available modes: Black on White | Yellow on Black

Open the original version of this page.